Jing Shi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jing Shi has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Jing Zhang
Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
7 shared publicationsKun Zhao
Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
7 shared publicationsWei Sun
Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
6 shared publicationsChuanxi Yang
Department of Cardiology, Medical School of Southeast University, Nanjing, China
5 shared publications- Xiangqing Kong
Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
5 shared publications Xiaoguang Wu
Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
3 shared publications
Latest Publications
- Open Access
- 19 February 2026
- Published by Springer Nature in Microbiome
- Vol. 14  (1)
Association between the gut microbiome and plasma metabolites linked to vocalization-based temperament in Merino sheep
Temperament, as a determinant of behavioural and emotional responses, has a substantial adaptive value in different environments. This study aims to invest
- 19 February 2026
- Published by Springer Nature in Microbiome
- Vol. 14  (1)
Open AccessAssociation between the gut microbiome and plasma metabolites linked to vocalization-based temperament in Merino sheep
Temperament, as a determinant of behavioural and emotional responses, has a substantial adaptive value in different environments. This study aims to invest
- Open Access
- 29 August 2025
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1662054
Correction: Comprehensive analysis of the transcriptome-wide m6A methylome of heart via MeRIP after birth: day 0 vs. day 7
Correction on: Yang C, Zhao K, Zhang J, Wu X, Sun W, Kong X and Shi J (2021) Comprehensive Analysis of the Transcriptome-Wide m6A Methylome of Heart via MeRIP After Birth: Day 0 vs. Day 7. Front. Cardiovasc. Med. 8:633631. doi: 10.3389/fcvm.2021.633631 In the published article, there was an error in Figure 1C and Figure 8A as published. Due to our mistake in combining images, GAPDH band in Figures 1C, and images for NRCMs staining in Figure 8A were misused. The corrected Figure 1C and Figure 8A appear below.The level of m6A in P7 rat heart was decreased compared to P0. (A, B) Representative immunofluorescence images of paraffin-embedded heart sections labeled with α-Actinin, Ki67,pH3,Aurora B,green;Ki67,pH3,Aurora B,and EDU,red;DAPI,blue. Scale bars,200 µm). (C, D) Protein expression levels of PCNA as determined by Western blotting (C) in heart tissue from P0 and P7 rats and the corresponding densitometric analyses (D). GAPDH was detected as the loading control. (E, F) Quantification of m6A in total RNA in heart tissue (E) and NRCMs (F) from P0 and P7 rats. N 3 per group. The results are expressed as means ± SEMs (NS indicates not significant, *P 0.05, **P 0.01, ***P 0.001, compared to the control group). (I), and Pfkfb2 (J) in P0 NRCMs transfected with si-NC or si-METTL3 after treated with 20µg/ml Actinomycin D for 0, 3 or 6 hours. (K) Protein expression levels of Dhcr24, Nacad, Slc16a3, and Slc7a5 in P0 NRCMs transfected with si-NC or si-METTL3 (up) and the corresponding densitometric analysis (down). (L-O) mRNA expression level of Dhcr24 (L), Nacad (M), Slc16a3 (N), and Slc7a5 (O) in P0 NRCMs transfected with si-NC or si-METTL3 after treated with 20 µg/ml Actinomycin D for 0, 3 or 6 h. GAPDH was detected as the loading control. *P 0.05, **P 0.01, ****P 0.001, *****P 0.0001, compared to the si-NC group.The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.In the published article, there was an error in Supplementary Figure 1. Due to our oversight during the review process, Supplementary Figure 1 did not use the latest images we revised back when the article was typesetting. The correct material statement appears below.
- 29 August 2025
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1662054
Open AccessCorrection: Comprehensive analysis of the transcriptome-wide m6A methylome of heart via MeRIP after birth: day 0 vs. day 7
Correction on: Yang C, Zhao K, Zhang J, Wu X, Sun W, Kong X and Shi J (2021) Comprehensive Analysis of the Transcriptome-Wide m6A Methylome of Heart via MeRIP After Birth: Day 0 vs. Day 7. Front. Cardiovasc. Med. 8:633631. doi: 10.3389/fcvm.2021.633631 In the published article, there was an error in Figure 1C and Figure 8A as published. Due to our mistake in combining images, GAPDH band in Figures 1C, and images for NRCMs staining in Figure 8A were misused. The corrected Figure 1C and Figure 8A appear below.The level of m6A in P7 rat heart was decreased compared to P0. (A, B) Representative immunofluorescence images of paraffin-embedded heart sections labeled with α-Actinin, Ki67,pH3,Aurora B,green;Ki67,pH3,Aurora B,and EDU,red;DAPI,blue. Scale bars,200 µm). (C, D) Protein expression levels of PCNA as determined by Western blotting (C) in heart tissue from P0 and P7 rats and the corresponding densitometric analyses (D). GAPDH was detected as the loading control. (E, F) Quantification of m6A in total RNA in heart tissue (E) and NRCMs (F) from P0 and P7 rats. N 3 per group. The results are expressed as means ± SEMs (NS indicates not significant, *P 0.05, **P 0.01, ***P 0.001, compared to the control group). (I), and Pfkfb2 (J) in P0 NRCMs transfected with si-NC or si-METTL3 after treated with 20µg/ml Actinomycin D for 0, 3 or 6 hours. (K) Protein expression levels of Dhcr24, Nacad, Slc16a3, and Slc7a5 in P0 NRCMs transfected with si-NC or si-METTL3 (up) and the corresponding densitometric analysis (down). (L-O) mRNA expression level of Dhcr24 (L), Nacad (M), Slc16a3 (N), and Slc7a5 (O) in P0 NRCMs transfected with si-NC or si-METTL3 after treated with 20 µg/ml Actinomycin D for 0, 3 or 6 h. GAPDH was detected as the loading control. *P 0.05, **P 0.01, ****P 0.001, *****P 0.0001, compared to the si-NC group.The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.In the published article, there was an error in Supplementary Figure 1. Due to our oversight during the review process, Supplementary Figure 1 did not use the latest images we revised back when the article was typesetting. The correct material statement appears below.
- RetractionOpen Access
- 13 February 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 11  (1) , 1
Retraction Note: METTL3 improves cardiomyocyte proliferation upon myocardial infarction via upregulating miR-17-3p in a DGCR8-dependent manner
- 13 February 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 11  (1) , 1
RetractionOpen AccessRetraction Note: METTL3 improves cardiomyocyte proliferation upon myocardial infarction via upregulating miR-17-3p in a DGCR8-dependent manner
- 10 April 2024
- Published by Elsevier in International Journal of Cardiology
- Vol. 407, 132026
Construction and validation of a nomogram for predicting remission of migraine patients with patent foramen ovale after closure
- 10 April 2024
- Published by Elsevier in International Journal of Cardiology
- Vol. 407, 132026
Construction and validation of a nomogram for predicting remission of migraine patients with patent foramen ovale after closure
- Open Access
- 1 January 2024
- Published by Tech Science Press in Congenital Heart Disease
- Vol. 19  (3) , 279-291
White Matter Lesions in Young-Middle Aged Migraineurs with Patent Foreman Ovale: A Case-Control Study
Background: White matter lesion (WML) is common in aging brain and is associated with cognitive impairment and dementia. However, recent studies reported an association between patent foramen ovale (PFO) and WML in migraineurs, especially in young, middle-aged migraineurs. Our retrospective, case-control study aims to describe the clinical characteristics of WML in this population and to explore potential risk factors. Methods: 226 patients with migraine and PFO were consecutively initially screened. Relevant factors were selected by the least absolute shrinkage and selection operator (LASSO) regression and multivariable logistic regression model. A Nomogram was employed to visualize the prediction model conveniently. The discrimination and calibration abilities were evaluated using the Receiver Operating Characteristic (ROC) curve, the Hosmer-Lemeshow test, and calibration curves. Results: One hundred and nineteen participants were ultimately enrolled in our study, with a median age of 36.9 ± 12.7 years and 80.7% of females. Brain magnetic resonance imaging MRI showed 67 (56.3%) patients had WML, whereas 52 (43.7%) patients were categorized into the non-WML group. LASSO regression screened out potential variables and subsequent multivariate analysis finally identified age, mean platelet volume, and fibrinogen (FIB) as independent predictive factors of WML. The area under the ROC curve (AUC) was 0.807. Hosmer-Lemeshow test and calibration curve verified a consistency between the predicted and actual probability. Conclusion: The predictive nomogram established and validated in our study may assist clinicians in screening WML among young middle-aged migraineurs with PFO and developing individualized preventive and treatment strategies.
- 1 January 2024
- Published by Tech Science Press in Congenital Heart Disease
- Vol. 19  (3) , 279-291
Open AccessWhite Matter Lesions in Young-Middle Aged Migraineurs with Patent Foreman Ovale: A Case-Control Study
Background: White matter lesion (WML) is common in aging brain and is associated with cognitive impairment and dementia. However, recent studies reported an association between patent foramen ovale (PFO) and WML in migraineurs, especially in young, middle-aged migraineurs. Our retrospective, case-control study aims to describe the clinical characteristics of WML in this population and to explore potential risk factors. Methods: 226 patients with migraine and PFO were consecutively initially screened. Relevant factors were selected by the least absolute shrinkage and selection operator (LASSO) regression and multivariable logistic regression model. A Nomogram was employed to visualize the prediction model conveniently. The discrimination and calibration abilities were evaluated using the Receiver Operating Characteristic (ROC) curve, the Hosmer-Lemeshow test, and calibration curves. Results: One hundred and nineteen participants were ultimately enrolled in our study, with a median age of 36.9 ± 12.7 years and 80.7% of females. Brain magnetic resonance imaging MRI showed 67 (56.3%) patients had WML, whereas 52 (43.7%) patients were categorized into the non-WML group. LASSO regression screened out potential variables and subsequent multivariate analysis finally identified age, mean platelet volume, and fibrinogen (FIB) as independent predictive factors of WML. The area under the ROC curve (AUC) was 0.807. Hosmer-Lemeshow test and calibration curve verified a consistency between the predicted and actual probability. Conclusion: The predictive nomogram established and validated in our study may assist clinicians in screening WML among young middle-aged migraineurs with PFO and developing individualized preventive and treatment strategies.
- Top Cited Papers
- 8 December 2023
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 133  (12) , 989-1002
NAT10 Is Involved in Cardiac Remodeling Through ac4C-Mediated Transcriptomic Regulation
BACKGROUND: Heart failure, characterized by cardiac remodeling, is associated with abnormal epigenetic processes and aberrant gene expression. Here, we aimed to elucidate the effects and mechanisms of NAT10 (N-acetyltransferase 10)-mediated N4-acetylcytidine (ac4C) acetylation during cardiac remodeling. METHODS: NAT10 and ac4C expression were detected in both human and mouse subjects with cardiac remodeling through multiple assays. Subsequently, acetylated RNA immunoprecipitation and sequencing, thiol-linked alkylation for the metabolic sequencing of RNA (SLAM-seq), and ribosome sequencing (Ribo-seq) were employed to elucidate the role of ac4C-modified posttranscriptional regulation in cardiac remodeling. Additionally, functional experiments involving the overexpression or knockdown of NAT10 were conducted in mice models challenged with Ang II (angiotensin II) and transverse aortic constriction. RESULTS: NAT10 expression and RNA ac4C levels were increased in in vitro and in vivo cardiac remodeling models, as well as in patients with cardiac hypertrophy. Silencing and inhibiting NAT10 attenuated Ang II-induced cardiomyocyte hypertrophy and cardiofibroblast activation. Next-generation sequencing revealed ac4C changes in both mice and humans with cardiac hypertrophy were associated with changes in global mRNA abundance, stability, and translation efficiency. Mechanistically, NAT10 could enhance the stability and translation efficiency of CD47 and ROCK2 transcripts by upregulating their mRNA ac4C modification, thereby resulting in an increase in their protein expression during cardiac remodeling. Furthermore, the administration of Remodelin, a NAT10 inhibitor, has been shown to prevent cardiac functional impairments in mice subjected to transverse aortic constriction by suppressing cardiac fibrosis, hypertrophy, and inflammatory responses, while also regulating the expression levels of CD47 and ROCK2 (Rho associated coiled-coil containing protein kinase 2). CONCLUSIONS: Therefore, our data suggest that modulating epitranscriptomic processes, such as ac4C acetylation through NAT10, may be a promising therapeutic target against cardiac remodeling.
- 8 December 2023
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 133  (12) , 989-1002
Top Cited PapersNAT10 Is Involved in Cardiac Remodeling Through ac4C-Mediated Transcriptomic Regulation
BACKGROUND: Heart failure, characterized by cardiac remodeling, is associated with abnormal epigenetic processes and aberrant gene expression. Here, we aimed to elucidate the effects and mechanisms of NAT10 (N-acetyltransferase 10)-mediated N4-acetylcytidine (ac4C) acetylation during cardiac remodeling. METHODS: NAT10 and ac4C expression were detected in both human and mouse subjects with cardiac remodeling through multiple assays. Subsequently, acetylated RNA immunoprecipitation and sequencing, thiol-linked alkylation for the metabolic sequencing of RNA (SLAM-seq), and ribosome sequencing (Ribo-seq) were employed to elucidate the role of ac4C-modified posttranscriptional regulation in cardiac remodeling. Additionally, functional experiments involving the overexpression or knockdown of NAT10 were conducted in mice models challenged with Ang II (angiotensin II) and transverse aortic constriction. RESULTS: NAT10 expression and RNA ac4C levels were increased in in vitro and in vivo cardiac remodeling models, as well as in patients with cardiac hypertrophy. Silencing and inhibiting NAT10 attenuated Ang II-induced cardiomyocyte hypertrophy and cardiofibroblast activation. Next-generation sequencing revealed ac4C changes in both mice and humans with cardiac hypertrophy were associated with changes in global mRNA abundance, stability, and translation efficiency. Mechanistically, NAT10 could enhance the stability and translation efficiency of CD47 and ROCK2 transcripts by upregulating their mRNA ac4C modification, thereby resulting in an increase in their protein expression during cardiac remodeling. Furthermore, the administration of Remodelin, a NAT10 inhibitor, has been shown to prevent cardiac functional impairments in mice subjected to transverse aortic constriction by suppressing cardiac fibrosis, hypertrophy, and inflammatory responses, while also regulating the expression levels of CD47 and ROCK2 (Rho associated coiled-coil containing protein kinase 2). CONCLUSIONS: Therefore, our data suggest that modulating epitranscriptomic processes, such as ac4C acetylation through NAT10, may be a promising therapeutic target against cardiac remodeling.
- 18 November 2022
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 33  (2) , 350-358
Association between migraine or severe headache and hypertension among US adults: A cross-sectional study
- 18 November 2022
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 33  (2) , 350-358
Association between migraine or severe headache and hypertension among US adults: A cross-sectional study
- RetractedOpen Access
- 13 October 2021
- Published by Springer Nature in Cell Death Discovery
- Vol. 7  (1) , 1-14
RETRACTED ARTICLE: METTL3 improves cardiomyocyte proliferation upon myocardial infarction via upregulating miR-17-3p in a DGCR8-dependent manner
Myocardial infarction (MI), one of the most severe types of heart attack, exerts a strong negative effect on heart muscle by causing a massive and rapid loss of cardiomyocytes. However, the existing therapies do little to improve cardiac regeneration. Due to the role of methyltransferase-like 3 (METTL3) in the physiological proliferation of cardiomyocytes, we aimed to determine whether METTL3 could also promote cardiomyocyte proliferation under pathological conditions and to elucidate the underlying mechanism. The effects of METTL3 on cardiomyocyte proliferation and apoptosis were investigated in an in vivo rat model of MI and in an in vitro model of neonatal rat cardiomyocytes (NRCMs) exposed to hypoxia. We found that METTL3 expression was downregulated in hypoxia-exposed NRCMs and MI-induced rats. Furthermore, METTL3 pretreatment enhanced cardiomyocyte proliferation and inhibited cardiomyocyte apoptosis under hypoxic or MI conditions, and silencing METTL3 had the opposite effects. Additionally, METTL3 overexpression upregulated miR-17-3p expression. The miR-17-3p agomir mimicked the pro-proliferative and antiapoptotic effects of METTL3 in hypoxia-exposed cells or rats with MI, while the miR-17-3p antagomir blocked these effects. Additionally, pretreatment with the RNA-binding protein DGCR8 also hampered the protective role of METTL3 in hypoxia-exposed cells. Overall, the current study indicated that METTL3 could improve cardiomyocyte proliferation and subsequently ameliorate MI in rats by upregulating proliferation-related miR-17-3p in a DGCR8-dependent pri-miRNA-processing manner.
- 13 October 2021
- Published by Springer Nature in Cell Death Discovery
- Vol. 7  (1) , 1-14
RetractedOpen AccessRETRACTED ARTICLE: METTL3 improves cardiomyocyte proliferation upon myocardial infarction via upregulating miR-17-3p in a DGCR8-dependent manner
Myocardial infarction (MI), one of the most severe types of heart attack, exerts a strong negative effect on heart muscle by causing a massive and rapid loss of cardiomyocytes. However, the existing therapies do little to improve cardiac regeneration. Due to the role of methyltransferase-like 3 (METTL3) in the physiological proliferation of cardiomyocytes, we aimed to determine whether METTL3 could also promote cardiomyocyte proliferation under pathological conditions and to elucidate the underlying mechanism. The effects of METTL3 on cardiomyocyte proliferation and apoptosis were investigated in an in vivo rat model of MI and in an in vitro model of neonatal rat cardiomyocytes (NRCMs) exposed to hypoxia. We found that METTL3 expression was downregulated in hypoxia-exposed NRCMs and MI-induced rats. Furthermore, METTL3 pretreatment enhanced cardiomyocyte proliferation and inhibited cardiomyocyte apoptosis under hypoxic or MI conditions, and silencing METTL3 had the opposite effects. Additionally, METTL3 overexpression upregulated miR-17-3p expression. The miR-17-3p agomir mimicked the pro-proliferative and antiapoptotic effects of METTL3 in hypoxia-exposed cells or rats with MI, while the miR-17-3p antagomir blocked these effects. Additionally, pretreatment with the RNA-binding protein DGCR8 also hampered the protective role of METTL3 in hypoxia-exposed cells. Overall, the current study indicated that METTL3 could improve cardiomyocyte proliferation and subsequently ameliorate MI in rats by upregulating proliferation-related miR-17-3p in a DGCR8-dependent pri-miRNA-processing manner.
- Open Access
- 19 May 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Prognostic and Immunological Role of mRNA ac4C Regulator NAT10 in Pan-Cancer: New Territory for Cancer Research?
Background: NAT10 (also known as human N-acetyltransferase-like protein) is a critical gene that regulates N4-acetylcytidine formation in RNA, similar to the multiple regulators of N6-methyladenosine. However, the underlying functions and mechanisms of NAT10 in tumor progression and immunology are unclear. Methods: In this study, we systematically analyzed the pan-cancer expression and correlations of NAT10, using databases including Oncomine, PrognoScan, GEPIA2, and Kaplan-Meier Plotter. The potential correlations of NAT10 with immune infiltration stages and gene marker sets were analyzed using the Tumor Immune Estimation Resource and GEPIA2. Results: Compared with normal tissues, NAT10 showed higher expression in most cancers based on combined data from TCGA and GTEx. In different datasets, high NAT10 expression was significantly correlated with poor prognosis in adrenocortical carcinoma, head and neck squamous cell carcinoma, liver hepatocellular carcinoma, kidney renal papillary cell carcinoma, and pheochromocytoma and paraganglioma. Moreover, there were significant positive correlations between NAT10 expression and immune infiltrates, including B cells, CD8+ T cells, CD4+ T cells, neutrophils, macrophages, dendritic cells, endothelial cells, and fibroblasts in LIHC. NAT10 expression showed strong correlations with diverse immune marker gene sets in LIHC. Conclusion: NAT10 expression affects the prognosis of pan-cancer patients and is significantly correlated with tumor immune infiltration. Furthermore, it represents a potential target for cancer therapy.
- 19 May 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Open AccessPrognostic and Immunological Role of mRNA ac4C Regulator NAT10 in Pan-Cancer: New Territory for Cancer Research?
Background: NAT10 (also known as human N-acetyltransferase-like protein) is a critical gene that regulates N4-acetylcytidine formation in RNA, similar to the multiple regulators of N6-methyladenosine. However, the underlying functions and mechanisms of NAT10 in tumor progression and immunology are unclear. Methods: In this study, we systematically analyzed the pan-cancer expression and correlations of NAT10, using databases including Oncomine, PrognoScan, GEPIA2, and Kaplan-Meier Plotter. The potential correlations of NAT10 with immune infiltration stages and gene marker sets were analyzed using the Tumor Immune Estimation Resource and GEPIA2. Results: Compared with normal tissues, NAT10 showed higher expression in most cancers based on combined data from TCGA and GTEx. In different datasets, high NAT10 expression was significantly correlated with poor prognosis in adrenocortical carcinoma, head and neck squamous cell carcinoma, liver hepatocellular carcinoma, kidney renal papillary cell carcinoma, and pheochromocytoma and paraganglioma. Moreover, there were significant positive correlations between NAT10 expression and immune infiltrates, including B cells, CD8+ T cells, CD4+ T cells, neutrophils, macrophages, dendritic cells, endothelial cells, and fibroblasts in LIHC. NAT10 expression showed strong correlations with diverse immune marker gene sets in LIHC. Conclusion: NAT10 expression affects the prognosis of pan-cancer patients and is significantly correlated with tumor immune infiltration. Furthermore, it represents a potential target for cancer therapy.
- Open Access
- 22 March 2021
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 8
Comprehensive Analysis of the Transcriptome-Wide m6A Methylome of Heart via MeRIP After Birth: Day 0 vs. Day 7
Aim: To systematically classify the profile of the RNA m6A modification landscape of neonatal heart regeneration.Materials and Methods: Cardiomyocyte proliferation markers were detected via immunostaining. The expression of m6A modification regulators was detected using quantitative real-time PCR (qPCR) and Western blotting. Genome-wide profiling of methylation-modified transcripts was conducted with methylation-modified RNA immunoprecipitation sequencing (m6A-RIP-seq) and RNA sequencing (RNA-seq). The Gene Expression Omnibus database (GEO) dataset was used to verify the hub genes.Results: METTL3 and the level of m6A modification in total RNA was lower in P7 rat hearts than in P0 ones. In all, 1,637 methylation peaks were differentially expressed using m6A-RIP-seq, with 84 upregulated and 1,553 downregulated. Furthermore, conjoint analyses of m6A-RIP-seq, RNA-seq, and GEO data generated eight potential hub genes with differentially expressed hypermethylated or hypomethylated m6A levels.Conclusion: Our data provided novel information on m6A modification changes between Day 0 and Day 7 cardiomyocytes, which identified that increased METTL3 expression may enhance the proliferative capacity of neonatal cardiomyocytes, providing a theoretical basis for future clinical studies on the direct regulation of m6A in the proliferative capacity of cardiomyocytes.
- 22 March 2021
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 8
Open AccessComprehensive Analysis of the Transcriptome-Wide m6A Methylome of Heart via MeRIP After Birth: Day 0 vs. Day 7
Aim: To systematically classify the profile of the RNA m6A modification landscape of neonatal heart regeneration.Materials and Methods: Cardiomyocyte proliferation markers were detected via immunostaining. The expression of m6A modification regulators was detected using quantitative real-time PCR (qPCR) and Western blotting. Genome-wide profiling of methylation-modified transcripts was conducted with methylation-modified RNA immunoprecipitation sequencing (m6A-RIP-seq) and RNA sequencing (RNA-seq). The Gene Expression Omnibus database (GEO) dataset was used to verify the hub genes.Results: METTL3 and the level of m6A modification in total RNA was lower in P7 rat hearts than in P0 ones. In all, 1,637 methylation peaks were differentially expressed using m6A-RIP-seq, with 84 upregulated and 1,553 downregulated. Furthermore, conjoint analyses of m6A-RIP-seq, RNA-seq, and GEO data generated eight potential hub genes with differentially expressed hypermethylated or hypomethylated m6A levels.Conclusion: Our data provided novel information on m6A modification changes between Day 0 and Day 7 cardiomyocytes, which identified that increased METTL3 expression may enhance the proliferative capacity of neonatal cardiomyocytes, providing a theoretical basis for future clinical studies on the direct regulation of m6A in the proliferative capacity of cardiomyocytes.